for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

82.65USD

Change

0.68(+0.83%)

Volume

2,391,212

Today's Range

81.68

 - 

82.80

52 Week Range

72.23

 - 

92.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
81.97
Open
82.27
Volume
2,391,212
3M AVG Volume
190.74
Today's High
82.80
Today's Low
81.68
52 Week High
92.55
52 Week Low
72.23
Shares Out (MIL)
2,545.98
Market Cap (MIL)
210,425.60
Forward P/E
--
Dividend (Yield %)
2.95

Next Event

Merck & Co Inc at Cowen HealthCare Conference

Latest Developments

More

Merck's Keytruda Combination Therapy Met Main Goal In Metastatic Triple-Negative Breast Cancer Study

Merck Announces Q4 GAAP Earnings Per Share Of $0.92

Merck Announces Spinoff Of Women'S Health, Trusted Legacy Brands And Biosimilars Products Into New Company

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Contact Info

2000 Galloping Hill Rd

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Jim Scholefield

Executive Vice President, Chief Information and Digital Officer

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Key Stats

1.89 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

40.1K

2018

42.3K

2019

46.8K

2020(E)

49.7K
EPS (USD)

2017

3.980

2018

4.340

2019

5.190

2020(E)

5.722
Price To Earnings (TTM)
21.54
Price To Sales (TTM)
4.49
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
20.64
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Merck's Keytruda Combination Therapy Met Main Goal In Metastatic Triple-Negative Breast Cancer Study

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AS FIRST-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)

BRIEF-Aduro Biotech Announces Milestone Achieved Under Merck Collaboration For Initiation Of Phase 2 Trial Of Anti-Cd27 Agonist Mk-5890 In Non-Small Cell Lung Cancer

* ADURO BIOTECH ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF PHASE 2 TRIAL OF ANTI-CD27 AGONIST MK-5890 IN NON-SMALL CELL LUNG CANCER

Merck to slim down with asset spinoff, focus on Keytruda, vaccines

Merck & Co Inc <MRK.N> said on Wednesday it will spin off its women's health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines.

Merck to spin-off women's health, biosimilar businesses

U.S. drugmaker Merck & Co Inc said on Wednesday it was planning to spin off its women's health, biosimilar drugs and legacy products into a new publicly traded company.

Merck's Keytruda wins U.S. FDA approval for bladder cancer

The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc's Keytruda for a hard-to-treat form of bladder cancer, making it the first new treatment for the cancer in more than two decades.

Merck's Keytruda wins U.S. FDA approval for bladder cancer

The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc's Keytruda for the treatment of a type of bladder cancer.

BRIEF-GenOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance

* GENOWAY ACQUIRES ADDITIONAL RIGHTS TO DEVELOP ALL ANIMAL CELL MODELS USING THE CRISPR/CAS9 SYSTEM

Merck's Keytruda shows mixed results in phase 3 trial for small cell lung cancer

Merck & Co said a phase 3 trial of cancer drug Keytruda in combination with chemotherapy showed an increase in the amount of time patients lived with small cell lung cancer without it getting worse, but did not extend overall survival.

CORRECTED-BRIEF-Merck's Keytruda Shows Mixed Results In Phase 3 Trial For Small Cell Lung Cancer

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED TO CHEMOTHERAPY ALONE AS FIRST-LINE TREATMENT FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER

AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer

Dec 30 - AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.

Merck says Ebola vaccine to be available at lowest access price for poor nations

Merck & Co <MRK.N> said on Friday it expects to make licensed doses of its recently approved Ebola vaccine available in the third quarter of 2020 and price the single-dose injection at the lowest possible access price for poor and middle-income countries.

Merck says Ebola vaccine to be available at lowest access price for poor nations

Merck & Co said on Friday it expects to make licensed doses of its recently approved Ebola vaccine available in the third quarter of 2020 and price the single-dose injection at the lowest possible access price for poor and middle-income countries.

Merck receives FDA approval for Ebola vaccine

The U.S. Food and Drug Administration said on Thursday it approved drugmaker Merck & Co's <MRK.N> Ebola vaccine Ervebo, making it the first FDA-authorised vaccine against the deadly virus.

US STOCKS-Wall St falls as health, tech shares drag, tariff deadline looms

* Indexes down: Dow 0.3%, S&P 500 0.22%, Nasdaq 0.26% (Updates to late afternoon)

Merck pushes deeper into targeted cancer therapy with $2.7 billion ArQule deal

Merck & Co Inc <MRK.N> said on Monday it would buy ArQule Inc <ARQL.O> for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.

Merck to buy cancer drug developer ArQule for $2.7 bln in cash

Merck & CO said on Monday it would buy cancer drug developer ArQule Inc for $2.7 billion in cash to beef up its portfolio of blood cancer treatments.

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

Merck and Bayer's heart drug meets main goal of late-stage study

Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.

Merck and Bayer's heart drug meets main goal of late-stage study

Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study. The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients...

Merck wins European approval for first-ever Ebola vaccine

U.S. drugmaker Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up